Your browser doesn't support javascript.
loading
Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.
Timmers, Maarten; Tesseur, Ina; Bogert, Jennifer; Zetterberg, Henrik; Blennow, Kaj; Börjesson-Hanson, Anne; Baquero, Miquel; Boada, Mercè; Randolph, Christopher; Tritsmans, Luc; Van Nueten, Luc; Engelborghs, Sebastiaan; Streffer, Johannes Rolf.
Afiliação
  • Timmers M; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. Electronic address: mtimmer3@its.jnj.com.
  • Tesseur I; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium.
  • Bogert J; Janssen Research and Development LLC, Raritan, NJ, USA.
  • Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistery Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institu
  • Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistery Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Börjesson-Hanson A; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Sahlgrenska University Hospital, Mölndal, Sweden; Clinical Trials, Theme Aging, Karolinska University Hospital, Stockholm, Sweden.
  • Baquero M; Neurology Department, Hospital Universitari I Politecnic La Fe, Valencia, Spain.
  • Boada M; Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
  • Randolph C; MedAvante-ProPhase, Hamilton, NJ, USA; Department of Neurology, Loyola University Medical Center, Maywood, IL, USA.
  • Tritsmans L; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium.
  • Van Nueten L; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium.
  • Engelborghs S; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Department of Neurology and Center for Neurosciences, UZ Brussel and Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Streffer JR; Janssen Research and Development, A Division of Janssen Pharmaceutica N.V., Beerse, Belgium; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
Neurobiol Aging ; 79: 131-141, 2019 07.
Article em En | MEDLINE | ID: mdl-31055223
ABSTRACT
Amyloid ß (Aß) and tau are key hallmark features of Alzheimer's disease (AD) neuropathology. The interplay of Aß and tau for cognitive impairment in early AD was examined with cross-sectional analysis, measured by cerebrospinal fluid biomarkers (Aß1-42, total tau [t-tau], and phosphorylated tau [p-tau181P]), and on cognitive performance by the repeatable battery for assessment of neuropsychological status (RBANS). Participants (n = 246) included cognitively normal (Aß-), mild cognitively impaired (Aß-), preclinical AD (Aß+), and prodromal AD (Aß+). Overall, cognitive scores (RBANS total scale score) had a moderate negative correlation to t-tau (n = 246; r = -0.434; p < 0.001) and p-tau181P (r = -0.389; p < 0.001). When classified by Aß status, this correlation to t-tau was applicable only in Aß+ participants (n = 139; r = -0.451, p < 0.001) but not Aß- participants (n = 107; r = 0.137, p = 0.16), with identical findings for p-tau. Both tau (p < 0.0001) and interaction of Aß1-42 with tau (p = 0.006) affected RBANS, but not Aß1-42 alone. Cognitive/memory performance correlated well with cerebrospinal fluid tau levels across early stages of AD, although the correlation is Aß dependent.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Peptídeos beta-Amiloides / Proteínas tau / Cognição / Doença de Alzheimer Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Peptídeos beta-Amiloides / Proteínas tau / Cognição / Doença de Alzheimer Tipo de estudo: Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article